BOSTON--(BUSINESS WIRE)--Gamida Cell, a leading cellular and immune therapeutics company, today announced the appointment of Jaren Madden as vice president, investor relations and corporate communications. Ms. Madden brings nearly 20 years of strategic communications experience to this new role at Gamida Cell, and will be responsible for the company’s engagement with the investment community as well as leading Gamida Cell’s media relations activities.
“We are pleased to welcome Jaren to our leadership team. She is a strategic leader with substantial experience building investor relations and corporate communications programs to cultivate relationships with multiple stakeholders, including investors, media and patient advocacy groups,” said Julian Adams, Ph.D., chairman and chief executive officer of Gamida Cell. “In particular, Jaren’s previous experience building communications programs in the areas of blood cancers and rare genetic diseases will be instrumental as we continue to advance Gamida Cell’s clinical programs.”
Ms. Madden joined Gamida Cell from Shire plc, where she served as the global head of research and development communications. Prior to joining Shire, Ms. Madden held roles of increasing responsibility at Infinity Pharmaceuticals, Inc. from 2010 to 2017, most recently as senior director, investor relations and corporate communications, where she developed the strategy for and oversaw the execution of the company’s investor relations and corporate communications initiatives. While at Infinity, Ms. Madden worked with the management team on multiple equity offerings, raising total net proceeds of over $240 million. Before joining Infinity, she held communications and investor relations roles at Feinstein Kean Healthcare, Alkermes plc and Vertex Pharmaceuticals, Inc.
About NiCord
NiCord, the company’s lead clinical program, is
under development as a universal bone marrow transplant solution for
patients with high-risk hematologic malignancies. NiCord has
demonstrated improved efficacy over standard cord blood, including fewer
bacterial and fungal infections and a reduction in duration of hospital
stays. NiCord has been granted breakthrough status by the U.S. Food and
Drug Administration, making it the first bone marrow transplant
alternative to receive this designation. It has also received U.S. and
EU orphan drug designation. A phase III study evaluating NiCord in
patients with leukemia and lymphoma is ongoing in the United States,
Europe and Asia (NCT02730299). For more information on NiCord clinical
trials, please visit www.clinicaltrials.gov.
About Gamida Cell
Gamida Cell is a leader in cellular and
immune therapeutics dedicated to treating patients with cancer and rare
genetic diseases. The company is building a diverse pipeline based on
its proprietary NAM technology platform to deliver transformative
medicines to patients in need of new treatment options. To learn more
about Gamida Cell, including current clinical studies, please visit www.gamida-cell.com.
